CIP2A protein expression in high-grade, high-stage bladder cancer

Cancer Medicine

Volumn 1, Issue 1, 2012, Pages 76-81

  Huang, Lisa P ^a   Savoly, Diana ^a   Sidi, Abraham A ^b,c   Adelson, Martin E ^a   Mordechai, Eli ^a   Trama, Jason P ^a  

^a LLC   (United States)

^b WOLFSON MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bladder cancer; Cancer biomarker; Cancer diagnostic; CIP2A; TCC

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; CHROMOSOME PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TRANSITIONAL CELL CARCINOMA;

EID: 84879419332     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.15     Document Type: Article

References (23)

1. Lamm, D. L., and F. M. Torti. 1996. Bladder cancer, 1996. CA Cancer J. Clin. 46:93-112.
2. Duncan, W., and P. M. Quilty. 1986. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother. Oncol. 7:299-310.
3. Stein, J. P., G. Lieskovsky, R. Cote, et al.2001. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J. Clin. Oncol. 19:666-675.
4. El Gehani, K., L. Al-Kikhia, F. Emaetig, K. Syrjanen, O. Al-Fituri, and A. Elzagheid. 2012. Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder. Libyan J. Med. 7:14694-14699.
5. Miyamoto, H., J. S. Miller, D. A. Fajardo, T. K. Lee, G. J. Netto, and J. I. Epstein. 2010. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol. Int. 60:1-8.
6. Sturgeon, C. M., M. J. Duffy, B. R. Hofmann, et al. 2011. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin. Chem. 56:e1-e48.
7. Soo Hoo, L., J. Y. Zhang, and E. K. Chan. 2002. Cloning and characterization of a novel 90 kDa "companion" auto-antigen of p62 overexpressed in cancer. Oncogene 21:5006-5015.
8. Junttila, M. R., P. Puustinen, M. Niemela, et al. 2007. CIP2A inhibits PP2A in human malignancies. Cell 130:51-62.
9. Junttila, M. R., and J. Westermarck. 2008. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 7:592-596.
10. Khanna, A., C. Bockelman, A. Hemmes, et al. 2009. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J. Natl. Cancer Inst. 101:793-805.
11. Basile, J. R., and R. Czerninski. 2010. The role of CIP2A in oral squamous cell carcinoma. Cancer Biol. Ther. 10:700-702.
12. Come, C., A. Laine, M. Chanrion, et al. 2009. CIP2A is associated with human breast cancer aggressivity. Clin. Cancer Res. 15:5092-5100.
13. Huang, L. P., M. E. Adelson, E. Mordechai, and J. P. TRAMA. 2011. CIP2A expression is elevated in cervical cancer. Cancer Biomarkers 8:309-317.
14. Li, W., Z. Ge, C. Liu, et al. 2008. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin. Cancer Res. 14:3722-3728.
15. Vaarala, M. H., M. R. Vaisanen, and A. Ristimaki. 2010. CIP2A expression is increased in prostate cancer. J. Exp. Clin. Cancer Res. 29:136.
16. Nguyen, M. L., R. M. Kraft, and J. A. Blaho. 2007. Susceptibility of cancer cells to herpes simplex virus-dependent apoptosis. J. Gen. Virol. 88:1866-1875.
17. Datta, A., M. E. Adelson, Y. Mogilevkin, E. Mordechai, A. A. Sidi, and J. P. Trama. 2011. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer 11:234.
18. Weiss, C., F. von Romer, G. Capalbo, et al. 2009. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 74:1455-1460.
19. Chen, K. F., C. Y. Liu, Y. C. Lin, et al. 2010. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29:6257-6266.
20. Chen, K. F., H. C. Yu, C. Y. Liu, et al. 2011. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol. Cancer Ther. 10:892-901.
21. Khanna, A., J. Okkeri, T. Bilgen, et al. 2011. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 6:e17979.
22. Zhao, D., Z. Liu, J. Ding, et al. 2011. Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. J. Med. Microbiol. 59:259-265.
23. Teng, H. W., S. H. Yang, J. K. Lin, et al. 2012. CIP2A is a predictor of poor prognosis in colon cancer. J. Gastrointest. Surg. 16:1037-1047.